Rates of upgrade of ICD recipients to CRT in clinical practice and the potential impact of the more liberal use of CRT at initial implant

PACE - Pacing and Clinical Electrophysiology

Volumn 35, Issue 1, 2012, Pages 73-80

  Scott, Paul A ^a,b   Whittaker, Andrew ^a   Zeb, Mehmood ^b   Watts, Edd ^b   Yue, Arthur M ^a   Roberts, Paul R ^b   Morgan, John M ^a,b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

arrhythmias; cardiac resynchronization therapy; heart failure; implantable cardioverter defibrillators

Indexed keywords

LEAD;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CHANNELOPATHY; CLINICAL PRACTICE; CONGENITAL HEART DISEASE; CORONARY ARTERY DISEASE; DEFIBRILLATOR; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; NONISCHEMIC CARDIOMYOPATHY; OBSERVATIONAL STUDY; QRS COMPLEX; RETROSPECTIVE STUDY; TREATMENT FAILURE;

CARDIAC RESYNCHRONIZATION THERAPY DEVICES; DEFIBRILLATORS, IMPLANTABLE; DEVICE REMOVAL; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PREVALENCE;

EID: 84855877239     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2011.03255.x     Document Type: Article

References (16)

1. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA, 3rd, Freedman RA, Gettes LS, Gillinov AM, et al,. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: Executive summary. Heart Rhythm 2008; 5: 934-955.
2. Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, Linker DT, Maggioni AP, et al,. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 2009; 120: 835-842.
3. Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R, Gottipaty V, et al,. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: Results from the REPLACE registry. Circulation 2010; 122: 1553-1561.
4. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA, 3rd, et al,. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329-1338.
5. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, et al,. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010; 363: 2385-2396.
6. National Institute for Health and Clinical Excellence. Implantable cardioverter defibrillators for arrhythmias. Available at: (accessed May 1, 2011).
7. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, Kerber RE, et al,. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002; 106: 2145-2161. (Pubitemid 35192824)
8. National Institute for Health and Clinical Excellence. Cardiac resynchronisation therapy for the treatment of heart failure. Available at: (accessed May 1, 2011).
9. Schoenfeld D., Partial residuals for the proportional hazards regression model. Biometrika 1982; 69: 239-241.
10. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML,. Analysis of mortality events in the multicenter automatic defibrillator implantation trial (MADIT-II). J Ame Coll Cardiol 2004; 43: 1459-1465. (Pubitemid 38496355)
11. Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F, Boehmer JP, et al,. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: Analysis from the sudden cardiac death in heart failure trial. Circulation 2009; 120: 2170-2176.
12. Paisey JR, Yue AM, Moore R, Betts TR, Roberts PR, Morgan JM,. Development of indications for cardiac resynchronisation therapy in the implantable cardioverter defibrillator population. Int J Cardiol 2005; 99: 187-190. (Pubitemid 40320787)
13. Cleland JG, Tageldien A, Maarouf N, Hobson N,. Patients with heart failure who require an implantable defibrillator should have cardiac resynchronisation routinely. Heart 2008; 94: 963-966. (Pubitemid 352039871)
14. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, et al,. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237. (Pubitemid 40110811)
15. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L,. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549. (Pubitemid 40517094)
16. Network Devices Survey Group. Heart rhythm devices: UK National Clinical Audit 2009. Available at: (accessed May 1, 2011).